The health policy landscape will most certainly be altered in 2021 as a result of the US Presidential election. No matter who wins the election, innovators will have to continue to justify the value of their products by demonstrating evidence of safety and efficacy to consumers. As healthcare spending and budgetary constraints continue to grow, cost considerations will become a more dominant consideration. Heading into 2021 and beyond, value assessment of new innovations will need to carefully consider 3 key trends: Covid-19, digital technology, and inequality. Read more here.
(Source: Jason Shafrin, Med City News, October 6, 2020)